Contraindications for Daflon (Diosmin/Hesperidin)
Daflon has no absolute contraindications documented in the medical literature, but should be avoided in patients with known hypersensitivity to diosmin, hesperidin, or other citrus-derived flavonoids. 1, 2
Primary Contraindication
- Known allergy or hypersensitivity to diosmin, hesperidin, or citrus-derived compounds represents the only documented contraindication to Daflon use 2, 3
Important Precautions and Relative Contraindications
Drug Interactions Requiring Caution
- Concurrent use with anticoagulants or antiplatelet agents requires careful monitoring, as diosmin exhibits inhibitory effects on different metabolic enzymes that could theoretically alter drug metabolism 3
- Patients taking CYP450 enzyme substrates (particularly CYP2C9, CYP1A2, or CYP3A4) should be monitored for potential interactions, though specific clinical interactions have not been well-documented 3
Special Populations
- Pregnancy and breastfeeding: Use with caution due to limited safety data in these populations, though no specific contraindications have been established 2, 3
- Pediatric patients: Safety and efficacy have not been established in children 2
Safety Profile
- Excellent tolerability: Clinical trials involving 183 patients demonstrated that Daflon has a safety profile similar to placebo, with only 3 patients (1.6%) withdrawing due to adverse effects 4
- Most common adverse events: Gastrointestinal symptoms (mild dyspepsia, nausea) and autonomic effects (headache, dizziness) occur rarely and are generally mild 2
- No organ toxicity: Toxicological studies have shown a favorable safety profile with no significant hepatic, renal, or hematologic toxicity 3
Clinical Context
Unlike anticoagulants (which have extensive contraindication lists including active bleeding, severe thrombocytopenia, recent CNS bleeding, and severe renal impairment 5), Daflon's mechanism as a venotonic and microcirculatory protective agent does not carry these same bleeding or organ-specific risks 1, 6.